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Abstract
Clinical significance of the pT4 category in colon cancer is increasing with several therapeutic implications. The aim of this study
was to evaluate variability in diagnosing pT4a colon cancer. Twelve pathologists classified 66 preselected scanned Hematoxylin/
Eosin-stained slides with tumor cells at a distance of 25–1500 μm (n = 22), 0–25 μm (n = 22), or on (n = 22) the peritoneal
surface. Inter- and intraobserver variability were calculated using Kappa statistics. For interlaboratory variability, pathology
reports of pT3 and pT4a colon cancer were extracted from the Dutch Pathology Registry between 2012 and 2015. The proportion
of pT4a (pT4a/(pT3+pT4a)) was compared between 33 laboratories. Potential risk of understaging was assessed by determining
the average number of blocks taken from pT3 and pT4a N0-2M0 tumors with metachronous peritoneal metastasis. Interobserver
variability among 12 pathologists was 0.50 (95%CI 0.41–0.60; moderate agreement). Intraobserver variability (8 pathologists)
was 0.71 (substantial agreement). A total of 7745 reports with pT3 or pT4aN0-2M0 colon cancer from 33 laboratories were
included for interlaboratory analysis. Median percentage of pT4awas 15.5% (range 3.2–24.6%). After adjustment for casemix, 8
labs diagnosed pT4a significantly less or more frequently than the median lab. Metachronous peritoneal metastases were
histologically verified in 170 of 6629 pT3 and in 129 of 1116 pT4a tumors, with a mean number of blocks of 4.03(SD 1.51)
and 4.78 (SD 1.76) taken from the primary tumors, respectively (p < 0.001). A substantial variability in diagnosing pT4a colon
cancer exists, both at pathologist and laboratory level. Diagnosis of pT4a stage appears to be challenging and there is a need for
standardizing assessment of this pathological entity.
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Introduction
A considerable group of colon cancer patients presents with
T4 tumors. The T4 category represents the most advanced
category with respect to local invasion [1] and is related to a
high risk of developing peritoneal metastases [2, 3].
Pathological (p)T4 includes two main entities of locally ad-
vanced growth, categorized as pT4a (peritoneal penetration)
and pT4b (adjacent organ/structure invasion) according to the
TNM 8th ed. [4]. Intensified treatment strategies for patients
with pT4 colon cancer are currently under investigation, in-
cluding adjuvant hyperthermic intraperitoneal chemotherapy
(HIPEC) and second-look laparoscopy, aiming at prevention
and early detection of peritoneal metastases [5–7].
Furthermore, current clinical guidelines recommend adjuvant
chemotherapy in stage II colon cancer in the presence of pT4
[8]. Based on a recent pooled analysis from six clinical trials,
pT4 is now used to inform the duration of adjuvant chemo-
therapy in stage III colon cancer [9]. Thus, the pT4 diagnosis
is becoming an increasingly important parameter for patient
management.
Parameters used for clinical decision-making should be
reliable and reproducible. Pathologists have been aware of
the problems with regard to the pT4 category [10–12], with
peritoneal penetration (pT4a) being a less straightforward di-
agnostic feature than often assumed. The TNM definition
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implies that full penetration of tumor cells through the perito-
neum is required for pT4a. However, some national guidelines
on histopathology reporting of colorectal cancer also allow
tumors that are close to or at the peritoneal surface to be
regarded as pT4a [13, 14]. This practice originates from stud-
ies showing that tumors that are close to or at the peritoneal
surface, especially in combination with certain reactive chang-
es, also carry negative prognostic impact and risk of peritoneal
metastases similar to tumors showing full peritoneal penetra-
tion [11, 15]. From these data, it has been concluded that
certain features could be allowed to represent pT4a in order
to prevent underdiagnosis of pT4a [4, 10, 11, 15, 16]. Another
difficulty with regard to the pT4a category is that microscopic
detection of pT4 is dependent on macroscopic specimen eval-
uation and meticulous sampling of resection specimens [10,
12]. With the increasing clinical importance of the pT4a cate-
gory, it should be clear how pathologists currently diagnose
and define pT4a. Studies exploring current pathological prac-
tice and variability in diagnosing pT4a colon cancer are
lacking.
The aim of this study was to evaluate inter- and
intraobserver variability in diagnosing pT4 among patholo-
gists on preselected slides, focusing on the distinction between
deeply invasive pT3 and pT4a. Furthermore, interlaboratory
variability and the average number of blocks taken from pT3
tumors comparedwith those from pT4a tumors for microscop-
ic analysis in case of histologically verified metachronous
peritoneal metastases were determined.
Methods
Inter- and intraobserver variability
A total of 66 Hematoxylin/Eosin-stained slides from colon
carcinomas (one slide per case) were selected. These slides
were selected by an experienced gastrointestinal pathologist
(PS) based on the following criteria: category 1 (n = 22), tu-
mors where the cancer cells approached the peritoneal surface
with a distance of 25–1500 μm to the surface; category 2 (n =
22), where the cancer cells were very close to or at the perito-
neal surface with a distance of 0–25 μm to the surface; cate-
gory 3 (n = 22), tumors showing full peritoneal penetration
with tumor cells being present on the surface. The slides were
scanned (Leica Aperio AT2, × 20 or × 40) and displayed dig-
itally to the pathologists using tEPIS, pathology image man-
agement and sharing (TraiT tEPIS). Twelve experienced
Dutch and Belgian pathologists agreed to assess the slides.
All pathologists had a special interest in gastrointestinal pa-
thology and worked at university (n = 6) or non-university
(n = 6) hospitals. The pathologists were asked to stage the
cases as either pT3 or pT4a. The pathologists were blinded
for any clinicopathological information and did not receive
any diagnostic guidelines or upfront training on how to diag-
nose pT4a cancers. Pathologists were asked to specify the
features they used to make their decision and to note any
diagnostic problems. For the intraobserver analysis, the slides
were presented to the pathologists in a different order for a
second round of scoring. To reduce recall bias, a minimum
time interval of 3 months between the first and second evalu-
ation was used.
For descriptive purposes, Shepherd’s classification of local
peritoneal involvement (LPI) was used to describe the cases,
i.e., tumor well off (LPI1), close to (LPI2), at (LPI3), or on
(LPI4) the peritoneal surface [15, 17], with or without meso-
thelial inflammatory, hyperplastic reactions and/or serosal ul-
ceration (suppl. table 1).
Interlaboratory variability and tumor sampling
analysis
For the interlaboratory variability analysis and tumor sam-
pling analysis, data were retrieved from the automated pathol-
ogy archive PALGA, the nationwide network and registry of
histopathology and cytopathology in the Netherlands. The
PALGA database contains excerpts of pathology reports from
all Dutch pathology laboratories (nationwide coverage since
1991) [18]. The scientific and privacy committee of PALGA
approved the study protocol.
All pathology reports of pT3 and pT4 colon cancers report-
ed between 2012 and 2015 were extracted from PALGA.
Patient identifiable data were pseudonymized. Based on the
deepest invasion described in the original reports, all tumors
were reclassified as pT3 (colon cancers invading through the
muscularis propria into pericolonic fat), pT4a (penetrating the
serosa), and pT4b (invading adherent tissues or organs) ac-
cording to TNM8 [4]. All pT4b tumor, rectal cancer, neuro-
endocrine tumor (NET), and other non-carcinoma and pathol-
ogy reports of revised cases were excluded. Patients with dis-
tant metastases at the time of diagnosis were excluded using
linkage with the Netherlands Cancer Registry [19], because T
category has less therapeutic consequences in stage IV.
Finally, only pT3 and pT4a tumors (pN0-2, cM0) were includ-
ed for analysis. In the case of multiple synchronous primary
pT3 or pT4a colon cancers, only the most advanced tumor per
patient was included. Metachronous primary pT3 or pT4a
colon cancers (resected in separate surgical procedures) were
regarded as separate entities and included for analysis.
To explore interlaboratory variability in diagnosing pT4a,
the proportion of pT4a (pT4a/(pT3+pT4a)) was determined
and compared between the laboratories [20, 21]. To adjust
for case mix and to detect variables that might explain varia-
tion in diagnosing pT4a between laboratories, multivariate
regression analysis was performed. Proportions of pT4a were
only used to display variability between the laboratories and
no assumption on quality of the included laboratories was
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made based on pT4a proportions. According to national
Dutch guidelines, at least 10 lymph nodes should be examined
for adequate staging (www.oncoline.nl). Percentages of cases
with ≥ 10 lymph nodes per laboratory and the number of
(pT3+pT4) colectomy specimens per laboratory were
compared to the proportions of pT4a cases.
To evaluate a potential risk of understaging, we hypothe-
sized that histologically proven metachronous peritoneal dis-
semination of a tumor that was initially staged as pT3 could be
related to a sampling error at the time of specimen dissection
by which an area of peritoneal penetration might have been
missed. For this analysis, patients with pT3 and pT4aN0-2M0
colon cancer who developed histologically verified
metachronous peritoneal metastases were identified from the
PALGA database. Peritoneal metastases were defined as peri-
toneal, omental, and/or ovarian metastases. The number of
tissue blocks submitted per primary tumor resection specimen
was retrieved from the pathology reports. In the Netherlands,
grossing of colorectal specimens is performed variously by
pathologists and laboratory technicians, mainly according to
local protocols and also according to the Dutch colorectal
cancer guideline (www.oncoline.nl, 2014). There is no
national guideline on the minimum number of blocks from
primary colon carcinoma.
Statistics
Kappa statistics were performed to assess the degree of inter-
observer variability (two-way random single-measures
intraclass correlation, ICC) and intraobserver variability
(Cohen’s kappa). Based on an estimated expected kappa of
0.8, 95%CI [0.7–0.9], two-sided testing, alpha 0.05, power
0.80, 12 pathologists and a pT4a ratio of 50%, a sample size
of 66 was necessary for measuring the ICC. A kappa of 0
means that the correlation is only due to chance, whereas a
kappa of 1 refers to a perfect correlation. Values in between 0
and 1 can be interpreted (arbitrarily) as follows [22]: < 0, poor;
0–0.20, slight; 0.21–0.4, fair; 0.41–0.60, moderate; 0.61–0.8,
substantial; and from 0.81, almost perfect.
For the interlaboratory variability analysis, laboratories
with less than 50 synoptic reports of pT3 or pT4a colon cancer
in the 4 years’ study period were excluded. The laboratory
with the median proportion of pT4a diagnoses (pT4a/(pT3+
pT4a)) served as a statistical reference point in order to ex-
plore variability (without implying the highest quality of this
laboratory). Crude odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated using univariable logistic re-
gression analyses. Variables were considered to be statistically
significant if the 95% CI did not include 1. After checking for
multicollinearity, statistically significant variables (age, sex,
year of pathology report, tumor location, histological type,
grade of differentiation, presence of lymphatic or vascular
invasion, and lymph node (pN) status) were included in
multivariable logistic regression analyses. Adjusted ORs and
95% CIs were calculated and compared between laboratories.
Spearman’s rank correlation coefficient was used to correlate
non-normally distributed continuous variables.
For the tumor sampling analysis, the mean number of tissue
blocks of pT3 versus pT4a colon cancers was compared using
Student’s t test for independent samples. A p value of < 0.05
was considered statistically significant. For normally distrib-
uted continuous variables, mean and standard deviation (SD)
were reported; for non-normally distributed continuous vari-
ables, median and interquartile range (IQR) were provided.
Statistical analyses were performed with SPSS version 24.
Results
Inter- and intraobserver variability
Between October and December 2016, 12 pathologists evalu-
ated 66 slides (1 slide per case). The overall ICC was 0.50
(95%CI 0.41–0.60; moderate). The ICCs for pathologists
working in university and non-university hospitals were 0.52
(95%CI 0.42–0.63) and 0.48, (95%CI 0.37–0.60), respective-
ly. In 43 (65%) of the cases, a consensus was reached (arbi-
trarily defined as ≥ 80% agreement). Twenty-five (58%) were
classified as pT3 and 18 cases (42%) as pT4a (suppl. table 2).
No consensus was reached for the remaining 23 cases (35%),
including 3 cases of category 1 (5%), 13 cases of category 2
(60%), and 7 cases of category 3 (32%).
Eight out of 12 pathologists re-evaluated the slides after
3 months. Cohen’s kappa for intraobserver variability for the
eight pathologists was 0.43, 0.60, 0.66, 0.67, 0.75, 0.78, 0.85,
and 0.93, respectively (median, 0.71), translating into a
change in diagnosis in 3–30% of cases.
Eight pathologists provided comments. A subsequent re-
view of the cases and the comments highlighted several issues
in differentiating between pT3 and pT4a. These issues can be
broadly subdivided into the following categories: definition of
the reference layer, relation of tumor cells to reference layer,
reactive changes, tissue defects and artifacts, distinction be-
tween reactive mesothelial cells and tumor cells, and areas in
which peritoneal penetration is easily missed. These issues are
summarized in Table 1 with examples displayed in Figs. 1, 2,
3, 4, and 5.
Interlaboratory variability
After applying the predefined exclusion criteria, 7745 cases
with pT3/pT4a cM0 from 33 laboratories were used for anal-
ysis (suppl. figure 2). The number of colon cancer resection
specimens synoptically registered per laboratory ranged from
58 to 797 (median 209, IQR 130–278.5). The median propor-
tion of pT4a cases was 15.5% (ranging from 3.2 to 24.6%)
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(Fig. 6). There was neither a linear association between the
number of colectomy specimens examined and the proportion
of pT4a cases (p = 0.310) nor between the percentage of cases
with ≥ 10 lymph nodes examined and the proportion of pT4a
cases (p = 0.282). It should be noted that a minimum threshold
of 10 examined lymph nodes is used in the Netherlands
(www.oncoline.nl, 2014) instead of 12 in many other
guidelines.
Factors significantly associated with a pT4a diagnosis in
univariable analysis were female sex, histological type,
presence of lymphatic or vascular invasion, presence of lymph
node metastases, and laboratory. These factors were included
in multivariable analysis to determine case mix–corrected
interlaboratory variability (suppl. table 3). Adjusted ORs for
the separate laboratories, compared with the reference labora-
tory, are shown in Fig. 7. In total, 8 laboratories (24.2%) sig-
nificantly differed in diagnosing pT4a compared with the me-
dian lab after adjusting for case mix. In one laboratory, pT4a
was diagnosed significantly more frequently and in seven lab-
oratories less frequently than in the median laboratory.
Table 1 Issues in differentiating
between pT3 and pT4a identified
during reassessment of the slides





Some pathologists regarded simply the surface as a reference point
while others required recognizable mesothelium to be present
and used that as a reference point. Others regarded the
mesothelium plus a thin layer of underlying submesothelial
tissue, i.e., serosal membrane, to be the reference point.
Relation of tumor cells
to reference layer
Some pathologists required tumor cells to be clearly present on the
surface for diagnosing pT4a (Fig. 1). Others considered tumor
cells with variable closeness to the surface to be sufficient for
pT4a (Figs. 2 and 3). Some pathologists mentioned that they
regarded tumor cell growth into (i.e., not through) the serosal
membrane as sufficient for pT4a.
Reactive changes Some pathologists used the absence of reactive changes as an
argument for pT3 (Fig. 4a), while the presence of reactive
changes of the mesothelium and the submesothelial tissue
was used as an additional argument for pT4a (Fig. 4b/c).
Other pathologists did not use reactive changes when
discriminating between pT3 and pT4a.
Tissue defects and artifacts The distinction between pT3 and pT4a was sometimes hindered by
various changes such as tissue damage (denuded mesothelium in
Fig. 3a, b; crushed stroma in Fig. 3a; and extensive hemorrhage
in Fig. 5a), leading to the choice for pT3 by default. Finally,
loose groups of tumor cells, located in clefts, were by some
pathologists considered peritoneal penetration while others
considered these as potential artifacts (floaters) (Fig. 5b).
Distinction between reactive
mesothelial and tumor cells
In case of difficulties with this distinction, the pathologists
mentioned performing additional immunohistochemical
stainings.
Specific areas with high chance
of overlooking peritoneal
penetration
In some cases areas of peritoneal tumor involvement were
missed (Fig. 5d/e) frequently in clefts (Fig. 5d).
Fig. 1 a, b Colon carcinomas
with tumor cells “on” the
peritoneal surface (H&E stains, ×
20) that could be regarded as LPI4
(category 3). In both cases,
consensus (> 80%) of pT4a was
reached. However, in each case, 1
or 2 pathologists preferred pT3
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Tumor sampling analysis
Of the 7745 selected pT3/pT4a cM0 colon cancer patients,
299 (3.8%) were identified as having histologically verified
metachronous peritoneal metastases at the 1st of April 2018
according to PALGA. In 170 of the 299 patients, the primary
tumor was classified as pT3, in the remaining 129 patients as
pT4a. Based on the PALGA database, the proportion of
metachronous peritoneal metastases was 170/6629 (2.6%)
for pT3 and 129/1116 (12%) for pT4a. The number of blocks
taken from the primary tumor was normally distributed. In
patients with metachronous peritoneal metastases, the mean
number of blocks sampled in pT3 tumors was 4.03 (SD 1.51),
which was significantly less than 4.78 blocks (SD 1.76) in
pT4a colon cancers (p < 0.001). For pT3 and pT4a tumors
with metachronous peritoneal metastases, the number of cases
with 5 or more blocks taken from the primary tumor was 31%
(53/170) and 49% (63/129), respectively (5 tissue blocks are a
recommended minimum according to the UK guidelines
[14]).
Discussion
In this study, we explored the current pathological practice of
diagnosing pT4a colon cancer. The main findings are a mod-
erate interobserver agreement in distinguishing pT4a from
deeply invasive pT3 and a substantial intraobserver agree-
ment. Most disagreements were found in cases with tumor
cells at a distance of 0–25 μm to the surface, but even
preselected slides with tumor cells on the peritoneal surface
resulted in disagreement. Also, after adjustment for case mix,
the proportion of pT4a colon cancers differed significantly
between the median laboratory and eight other laboratories
(24%). Furthermore, pT3 tumors from patients who subse-
quently developed peritoneal metastases were diagnosed
using significantly lower number of tissue blocks than for
the diagnosis of pT4a tumors from patients who developed
peritoneal metastases. Our findings highlight inconsistencies
in diagnosing pT4a in colon cancers. Because the pT4 cate-
gory increasingly bears clinical and therapeutic consequences,
there is an urgent need for a better definition of the pT4a
category, which can be applied by pathologists in a reliable
and reproducible fashion.
Studies evaluating the practice of diagnosing pT4a colon
cancer at a pathologist and/or laboratory level are scarce.
Littleford et al. [23] determined interobserver variability of
the four categories of Shepherd’s LPI classification, using a
single-center cohort of 138 cases of pT3/pT4 cases. Kappa
values ranged between 0.45 and 0.64 among four pathologists
assessing the separate LPI categories, which is similar to the
present study [23]. Agreement increased when only LPI1–2
had to be discriminated fromLPI3–4, with Kappa values rang-
ing from 0.74 to 0.89.
Detailed macroscopic examination and subsequent exten-
sive sampling of suspected areas have been described to likely
improve the accuracy of pT4a assessment [12, 17], although
studies on the subject are still limited. Our study is the first to
show that pT4a is likely missed in some pT3 cases due to
inadequate sampling. In a recent guideline from the Royal
Fig. 2 Colon carcinomas with
tumor cells close to the peritoneal
surface (distance to peritoneal
surface, 60–200 μm (category 1);
H&E stains, × 20) that could be
regarded LPI2. In all cases,
consensus (> 80%) of pT3 was
reached; however, in all cases,
still 1 or 2 pathologists preferred
pT4a
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College of Pathologists, UK, it is recommended that a mini-
mum of 5 blocks should be taken from the primary tumor for
an accurate assessment of various pathology parameters [14].
Data from the present study appear to support this, with an
average of approximately 5 tissue blocks being taken from
primary pT4a tumors that developed peritoneal metastases,
as opposed an approximate average of 4 tissue blocks from
pT3 tumors that developed peritoneal metastases. Currently,
the Dutch colorectal cancer guideline does not contain any
recommendation on the minimum number of blocks from
the primary tumor for accurate assessment of pT status. In
the current study, 4 tumor blocks or less, i.e., less than the
minimum of 5 blocks according to the UK guideline, were
submitted in 61% of analyzed cases (183/299). Also, the low
frequency of pT4a in some of the laboratories (Fig. 6) likely
represents underdetection. An optimal pT4a detection rate for
stage II and III tumors is not known but a threshold of 20% for
pT4a+b in all stages combined has been recommended in the
UK [4]. The current data raise the question if a minimum
number of blocks from the primary tumor for pT assessment
need to be put forward in the Dutch guidelines and implement-
ed as an audit and quality criterion, similar to the minimum
number of examined lymph nodes.
In this study, we observed different approaches among pa-
thologists to diagnose pT3 or pT4a. Various criteria were ap-
plied, some of which being highly subjective and often incon-
sistently used. Most discrepancies among pathologists can be
traced back to two main schools of thoughts, one of them
being more strict and requiring cells to be growing through
the peritoneum and be present on the peritoneal surface
(Fig. 1, LPI4), while the other is less prescriptive with pT4a
already being considered when tumor cells are close to or at
the peritoneal surface (LPI2/3), especially in the presence of
particular reactive changes.
Attempts have been made to further define the pT4a cate-
gory in the literature. The main UICC and AJCC TNM
Fig. 3 a–d Colon carcinomas
with tumor cells very close to or
“at” the peritoneal surface (H&E
stains, × 20) that could be
regarded LPI3 (distance of tumor
cells to the peritoneal surface
measured 25 μm or less (category
2)). No consensus was reached in
cases a, b, c, and d (classified as
pT4a by 4/12, 5/12, 5/12, and
9/12 pathologists, respectively).
Although similar to the other
cases in Fig. 3, consensus of pT3
was reached for cases e and f
(considered as pT4a by 2/12 and
1/12 pathologists, respectively)
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definition of pT4a, i.e., tumor that perforates visceral
peritoneum, has hardly changed during the last 20–30 years
except that in the AJCC 7th and 8th edition, the word
perforates was exchanged with the word penetrates and
invades, respectively. In some national guidelines, further de-
tails on the definition of pT4a have been put forward. In both
the US and UK guidelines, this is based on the LPI categori-
zation by Shepherd et al. [15, 17]. In the College of American
Pathologists guideline from 2017, the pT4a definition in-
cludes tumor present at the serosal surface and free tumor
cells on the serosal surface with underlying erosion/
ulceration of mesothelial lining, mesothelial hyperplasia
and/or inflammatory reaction (roughly equates to LPI3 and
4) [13]. In the current UK guideline from 2018, pT4a is de-
fined as tumor cells visible either on the peritoneal surface,
free in the peritoneal cavity or separated from the peritoneal
surface by inflammatory cells only (also roughly LPI3 and 4)
[14]. In the Netherlands, the national guideline on colorectal
cancer does not give any details on the definition of pT4a
beyond the TNM literature (www.oncoline.nl). The LPI
Fig. 4 a–f Examples of cases with tumor cells or mucin close to or at the
peritoneal surface with and without reactive changes (H&E stains, × 10
and × 20). In case a (classified pT4a by 2/12 pathologists), the lack of
reactive changes wasmentioned by some as the reason for preferring pT3.
No consensus was reached in case b. Some pathologists mentioned the
presence of serosal reaction, while others contradictorily described the
lack of serosal reaction in this case, indicating that serosal reaction is a
subjective parameter. In case c, consensus of pT3 was reached. Still, one
pathologist chose T4a based on the reactive changes with the lack of a
clear mesothelial lining. For other pathologists, the amount of tissue
between the tumor cells and the surface was used as an argument for
pT3. These cases demonstrate inconsistency in applying reactive
changes when distinguishing between pT3 and pT4a
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classification might be suboptimal because the distinction
between LPI2 and LPI3 may be unclear in many cases
where tumor cells approach the peritoneal surface. Also, a
gradient in prognostic impact within the LPI3 category has
been described [24]. Recently, some authors have proposed
that colon cancers 1 mm or less from the serosal surface
should be regarded as pT4a when additionally displaying
certain features (serosal fibroinflammatory reaction;
peritumoral abscesses that communicate with the serosa;
serosal hemorrhage; and serosal fibrin) [11]. Other authors
have proposed that invasion beyond the peritoneal elastic
lamina should be regarded as pT4a [25]. Various proposed
additional criteria for diagnosing pT4a may, however,
contradict one of the general rules of the TNM system that
states that if there is doubt concerning the correct T, N or M
category to which a particular case should be allotted, then
the lower (i.e., less advanced) category should be chosen [4].
Variation in guidelines and literature suggestions regarding the
pT4a definition has likely contributed to the confusion in what
represents pT4a [26].
Defining pT4 has been mainly based on survival, and sel-
dom on the risk of metachronous peritoneal metastases. The
Fig. 5 Colon carcinomas with tumor cells close to the peritoneal surface
(H&E stains). Case a, presence of subsurface hemorrhage (× 4 and × 20)
(classified pT4a by 10/12 pathologists). Case b, groups of tumor cells in a
cleft (classified pT4a by 5/12 pathologists). By some, this was considered
as a (potential) artifact. Also, case b shows ink on the surface which was
mentioned as obscuring some of themorphological details, thus hindering
assessment. Case c (× 10), reactive mesothelial cells in a cleft (arrow)
resembling sheets of tumor cells that are in the vicinity (arrowhead)
(classified pT4a by 3/12 pathologists). Cases d and e demonstrate
peritoneal involvement that is likely to have been missed. Case d,
peritoneal cleft buried inside the slide (arrows), focally (arrowhead)
showing full penetration of tumor cells (inlet photo) (classified pT4a by
3/12 pathologists). Case e, most of the pathologists assessed only the
peritoneal surface in front of the tumor (arrowhead) and missed the flat
peritoneal surface on the side of the slide (arrow) showing tumor cells
very close to the surface (classified pT4a by 2/12 pathologists)
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upcoming treatment strategies for peritoneal metastases justify
consideration of the risk of peritoneal metastases when defin-
ing pT4. Shepherd [15] reported that peritoneal recurrences all
occurred in the LPI3 and 4 group except for one case in the
LPI2 group (1%). In a recent series [27] of 159 patients, the 5-
year peritoneal recurrence rate was 33% for true peritoneal
penetration (LPI4), as opposed to 21% (p = 0.057) for perito-
neal reaction with tumor less than 1 mm from the peritoneum
(LPI2–3). Using peritoneal scrape cytology [11], tumor cells
were found in 46% and 55% of the deeply invasive pT3 and
pT4a tumors (vs. 19% in all pT3), translating into peritoneal
recurrence rates of 11% and 18%, respectively. These data
show that the presence of tumor cells on the peritoneal surface
carries a higher risk of peritoneal metastases than when tumor
cells are close to or at the surface but without full penetration.
Although the risk of local, peritoneal, or systemic recurrence
is also increased in these deeply invasive pT3 cases, it remains
unclear whether that justifies including them into the pT4a
category.
There are some limitations related to the present study.
Regarding the interobserver variability analysis, the select-
ed samples might not have been a realistic representation
of daily clinical practice, also since deeper levels and
analyzing/adding more tumor sections was not possible in
the present research setting, potentially leading to an un-
derestimation of interobserver agreement. We rather
choose this design in order to identify pitfalls and points
of attention. In addition, virtual slide analysis requires
training and may be less efficient on this kind of material.
In the interlaboratory analysis, the use of the median labo-
ratory as a reference is convenient for describing the level
of variation that exists between laboratories [20, 21]. This
study does not attempt to provide information on which
frequency of pT4a would be optimal. Finally, the sampling
analysis might be confounded by for example fewer blocks
being taken from areas grossly suspicious of T4a and by var-
iability in microscopic assessment. Despite these shortcom-
ings, we were able to demonstrate a difference in the number
of tissue block between pT3 and pT4a cases, which may even
strengthen our finding. It should also be mentioned that the
frequency of peritoneal metastases is most likely
underreported in this series, as in daily clinical practice, not














































































Fig. 7 Adjusted OR’s per laboratory. Laboratory 0 is the reference
laboratory based on the median. Asterisk indicates laboratories that
significantly differed from the reference laboratory. Total, total numbers
of pT3-4aN0-2M0 specimens evaluated in each laboratory
Fig. 6 Proportion of pT4a
diagnoses per laboratory for pT3-
4aN0-2M0 colorectal carcinomas
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We conclude that the current pathology practice leaves
room for subjectivity and variable interpretation when
distinguishing pT3 from pT4a colon cancer. Also, the current
literature on the topic is limited and does not offer enough data
on how pT3 and pT4a should be distinguished. Considering
the potential therapeutic and prognostic implications, the re-
producibility of pT4a diagnosis should be improved, both
with regard to sampling and microscopic assessment.
Especially, the gray area of peritoneal involvement should
be clarified with explicit criteria to distinguish pT4a from
pT3. To achieve this, future research should aim at assessing
the histopathology of pT3-pT4a within clinical trials with de-
tailed follow-up regarding peritoneal recurrences.
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